Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical Trial Analysis research report provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical trials scenario. This report provides top-line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials.
What is the regional and country-wise outlook in the Familial Hypercholesterolemia clinical trials market?
The Familial Hypercholesterolemia clinical trials market is the largest in the Asia Pacific, followed by Europe, North America, the Middle East and Africa, and South and Central America. In a country-wise analysis, as of May 2022, the US has the highest number of Familial Hypercholesterolemia clinical trials, followed by China, Canada, Netherlands, Russia, South Korea, the UK, South Africa, Germany, and Norway. The UK has the highest average patient enrollment in Familial Hypercholesterolemia clinical trials.
G7 countries:
Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada and Japan) countries, Canada has the highest proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to metabolic disorders clinical trials. Moreover, out of all the clinical trials conducted in the G7 countries, the majority were in the US.
E7 countries:
Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to metabolic disorders clinical trials. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
Familial Hypercholesterolemia clinical trials market, by region
For more regional insights, download a free report sample
What are the key sponsor types in the Familial Hypercholesterolemia clinical trials market?
The key sponsor types in the Familial Hypercholesterolemia clinical trials market are institution, company, and government. Out of them, company dominates the market.
Familial Hypercholesterolemia clinical trials market, by sponsor types
For more sponsor type insights, download a free report sample
Which are the key companies in the Familial Hypercholesterolemia clinical trials market?
The key companies in the Familial Hypercholesterolemia clinical trials market are Sanofi, Regeneron Pharmaceuticals Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, Medpace Holdings Inc, Merck & Co Inc, Amryt Pharma Plc, Amgen Inc, Organon & Co, and Dr. Reddy’s Laboratories Ltd.
Familial Hypercholesterolemia clinical trials market, by companies
To know more about companies, download a free report sample
Market report overview
Key regions | Asia-Pacific, Europe, Northern America, Middle East and Africa, and South and Central America |
Key countries | The US, China, Canada, Netherlands, Russia, South Korea, the UK, South Africa, Germany, and Norway |
Key sponsor types | Institution, Company, and Government |
Key companies | Sanofi, Regeneron Pharmaceuticals Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, Medpace Holdings Inc, Merck & Co Inc, Amryt Pharma Plc, Amgen Inc, Organon & Co, and Dr. Reddy’s Laboratories Ltd |
Scope
The report provides:
- A snapshot of the global clinical trials landscape.
- Top level data related to the clinical trials by region, country, trial status, trial phase, sponsor type, and end point status.
- Reviews of top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- All the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- Enrollment trends for the past five years.
- Latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Regeneron Pharmaceuticals Inc
Novartis AG
Teva Pharmaceutical Industries Ltd
Medpace Holdings Inc
Merck & Co Inc
Amryt Pharma Plc
Amgen Inc
Organon & Co
Dr. Reddy's Laboratories Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the Familial Hypercholesterolemia clinical trials market?
The key regions in the Familial Hypercholesterolemia clinical trials market are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America.
-
Which are the key countries in the Familial Hypercholesterolemia clinical trials market?
The key countries in the Familial Hypercholesterolemia clinical trials market are the US, China, Canada, Netherlands, Russia, South Korea, the UK, South Africa, Germany, and Norway.
-
What are the key sponsor types in the Familial Hypercholesterolemia clinical trials market?
The key sponsor types in the Familial Hypercholesterolemia clinical trials market are institution, company, and government.
-
Which are the key companies in the Familial Hypercholesterolemia clinical trials market?
The key companies in the Familial Hypercholesterolemia clinical trials market are Sanofi, Regeneron Pharmaceuticals Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, Medpace Holdings Inc, Merck & Co Inc, Amryt Pharma Plc, Amgen Inc, Organon & Co, and Dr. Reddy’s Laboratories Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Metabolic Disorders reports![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)